ALPMF (Astellas Pharma) Interest Income: $73 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALPMF Astellas Pharma Inc ALPMF
86 GF Score
Price $16.05
GF Value $14.75
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Astellas Pharma Interest Income?

Astellas Pharma ALPMF +7.72% 86 Interest Income is $73 Mil as of Jun. 2026. GuruFocus rates ALPMF with a GF Score™ of 86/100 and a GF Value™ of $14.75 (Fairly Valued). The stock has 5 warning signs investors should review.

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Astellas Pharma's interest income for the three months ended in Jun. 2026 was $32 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2026 was $73 Mil.

Astellas Pharma Interest Income Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Interest Income Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.86 60.67 76.46 52.83 50.58

Astellas Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.54 14.55 12.19 14.53 31.91
ALPMF
86GF Score
Astellas Pharma Inc ALPMF
Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Income →
What does a Interest Income of $73 Mil mean?
Astellas Pharma (ALPMF) has a Interest Income of $73 Mil as of Jun. 2026. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Interest Income too high?
Astellas Pharma's current Interest Income is $73 Mil. Overall, Astellas Pharma has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Interest Income compare to LLY and JNJ?
Astellas Pharma's Interest Income of $73 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Income for a Drug Manufacturers company?
A good Interest Income depends on the Drug Manufacturers industry context. However, Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Income mean?
A high Interest Income can signal that a stock is expensive relative to its fundamentals. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Interest Income is $73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.75, compared to a current price of $16.05 — trading 8.8% above its estimated fair value. The current Interest Income is $73 Mil. Astellas Pharma's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Income calculated?
Interest Income is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Interest Income is $73 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued. The current stock price of $16.05 is trading 8.8% above its estimated GF Value™ of $14.75. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

  • Interest Income: $73 Mil
  • GF Value™: $14.75 vs. price of $16.05 (8.8% above fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
86GF Score

Get the complete analysis for ALPMF

Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.05
Price
$14.75
GF Value